The Upside Potential in Editas Medicine Stock
Editas has key collaboration agreements with Juno Therapeutics and Allergan Pharmaceuticals. Of the nine analysts covering Editas Medicine in May, five have given the stock “buy” or higher ratings, three have given it “hold” ratings, and one has given it a “strong sell” rating. The mean rating for the stock is 2.67, and its target price is $45.2, implying an upside potential of 23.4% over its closing price of $36.63 on May 24.